Working… Menu

Medication Optimisation for Reducing Events in a Private Practice Setting (MORE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00653653
Recruitment Status : Unknown
Verified April 2009 by Awenydd GmbH.
Recruitment status was:  Active, not recruiting
First Posted : April 7, 2008
Last Update Posted : April 8, 2009
Information provided by:
Awenydd GmbH

Brief Summary:

Using a prospective study design of two three month periods (before and after genotyping) in which the patients will self-monitor their health status and possible medical events it is hypothesized that it will be shown that patients having their medication altered to fit their genetic status and/or having their medication altered because of inherent interaction potential will have less recordable events after genotyping and medical analysis than before.

It is well known that ADRs (recordable adverse events to medication) are responsible for a large number of deaths and hospitalizations. Furthermore it is well recorded that genotyping of individual cytochrome P450 enzymes (2D6, 2C9, 2C19, among others) is directly related to a metabolic phenotype - fast metabolisers, slow metabolisers, intermediate and normal metabolisers. These differing phenotypes have altered metabolism of many medications and in a number of retrospective clinical trails it has been shown that ADRs and effect can be reduced/bettered through genotyping and alteration of medication.

Condition or disease
Pharmacogenetic Analysis to Reduce Events.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study of the Pharmaco-Economic and Medical Effects of Optimising Medication Using Pharmacokinetic Pharmacogenomics and Medication Interaction Analysis in Private Practice.
Study Start Date : August 2008
Estimated Primary Completion Date : June 2009
Estimated Study Completion Date : October 2009

Group A
Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.

Primary Outcome Measures :
  1. Reduction of reported events in the time frame. [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Reduction of total costs associated per patient in the time frame. [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Community sample.

Inclusion Criteria:

  • older than 18 years
  • not demented
  • 1 or more documented events in the previous 6 months.
  • more than one medication
  • multi-morbid

Exclusion Criteria:

  • demented
  • life expectancy less than 1 year
  • heart attack within the last 6 months
  • Marcumar® Therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00653653

Layout table for location information
Awenydd Gmbh
Köln, NRW, Germany, 50829
Sponsors and Collaborators
Awenydd GmbH
Layout table for investigator information
Study Director: Lee S Griffith, Ph.D. Awenydd GmbH
Principal Investigator: André Gessner, MD Ph.D. University of Erlangen-Nürnberg
Layout table for additonal information
Responsible Party: Dr. LS Griffith, awenydd Gene Diagnostic Identifier: NCT00653653    
Other Study ID Numbers: AW_SH_08
First Posted: April 7, 2008    Key Record Dates
Last Update Posted: April 8, 2009
Last Verified: April 2009
Keywords provided by Awenydd GmbH:
adverse events
drug metabolism